Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021804 | 0.84 | SRD5A2 (0.55) | HSD11B1 | |
| SCHEMBL2879876 | 0.84 | SRD5A2 (0.55) | HSD11B1 | |
| SCHEMBL15457758 | 0.83 | MAOB (0.47) | MAOB | |
| SCHEMBL10165226 | 0.82 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL13100303 | 0.82 | SMN1; SMN2 (0.59) | — | |
| SCHEMBL11940939 | 0.82 | MAOB (0.46) | MAOB | |
| SCHEMBL20494379 | 0.82 | MAOB (0.46) | MAOB | |
| SCHEMBL18290647 | 0.81 | MAOB (0.49) | MAOB | |
| SCHEMBL15582362 | 0.80 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL1019905 | 0.79 | HSD11B1 (0.50) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | HSD11B1 4118/4885MAOB 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.